Published : Aug-2017
No. of Pages : 124
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 8
2 Introduction 9
2.1 Artificial Pancreas Overview 9
3 Products under Development 10
3.1 Artificial Pancreas - Pipeline Products by Stage of Development 10
3.2 Artificial Pancreas - Pipeline Products by Territory 11
3.3 Artificial Pancreas - Pipeline Products by Regulatory Path 12
3.4 Artificial Pancreas - Pipeline Products by Estimated Approval Date 13
3.5 Artificial Pancreas - Ongoing Clinical Trials 14
4 Artificial Pancreas - Pipeline Products under Development by Companies 15
4.1 Artificial Pancreas Companies - Pipeline Products by Stage of Development 15
4.2 Artificial Pancreas - Pipeline Products by Stage of Development 17
5 Artificial Pancreas Companies and Product Overview 19
5.1 Admetsys Corporation Company Overview 19
5.1.1 Admetsys Corporation Pipeline Products & Ongoing Clinical Trials Overview 19
5.2 Advanced Biosensors-Ohio, Llc Company Overview 20
5.2.1 Advanced Biosensors-Ohio, Llc Pipeline Products & Ongoing Clinical Trials Overview 20
5.3 Animas Corp Company Overview 21
5.3.1 Animas Corp Pipeline Products & Ongoing Clinical Trials Overview 21
5.4 Beta Bionics Inc Company Overview 22
5.4.1 Beta Bionics Inc Pipeline Products & Ongoing Clinical Trials Overview 22
5.5 Beta-O2 Technologies Ltd Company Overview 25
5.5.1 Beta-O2 Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 25
5.6 Bigfoot Biomedical, Inc. Company Overview 28
5.6.1 Bigfoot Biomedical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 28
5.7 BioTex Inc Company Overview 29
5.7.1 BioTex Inc Pipeline Products & Ongoing Clinical Trials Overview 29
5.8 Cerco Medical LLC Company Overview 30
5.8.1 Cerco Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 30
5.9 Converge Biotech, Inc. Company Overview 31
5.9.1 Converge Biotech, Inc. Pipeline Products & Ongoing Clinical Trials Overview 31
5.10 Covalor Medical, LLC Company Overview 32
5.10.1 Covalor Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview 32
5.11 De Montfort University Company Overview 33
5.11.1 De Montfort University Pipeline Products & Ongoing Clinical Trials Overview 33
5.12 Debiotech SA Company Overview 34
5.12.1 Debiotech SA Pipeline Products & Ongoing Clinical Trials Overview 34
5.13 Defymed Inc Company Overview 35
5.13.1 Defymed Inc Pipeline Products & Ongoing Clinical Trials Overview 35
5.14 Diabeloop Company Overview 36
5.14.1 Diabeloop Pipeline Products & Ongoing Clinical Trials Overview 36
5.15 Giner Inc Company Overview 39
5.15.1 Giner Inc Pipeline Products & Ongoing Clinical Trials Overview 39
5.16 Imperial College London Company Overview 40
5.16.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 40
5.17 Inreda Diabetic BV Company Overview 41
5.17.1 Inreda Diabetic BV Pipeline Products & Ongoing Clinical Trials Overview 41
5.18 Insulet Corp Company Overview 42
5.18.1 Insulet Corp Pipeline Products & Ongoing Clinical Trials Overview 42
5.19 Kencak LLC Company Overview 43
5.19.1 Kencak LLC Pipeline Products & Ongoing Clinical Trials Overview 43
5.20 Medtronic plc Company Overview 44
5.20.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 44
5.21 Miromatrix Medical Inc Company Overview 52
5.21.1 Miromatrix Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 52
5.22 Nikkiso Co., Ltd. Company Overview 53
5.22.1 Nikkiso Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 53
5.23 Pacific Diabetes Technologies, Inc. Company Overview 54
5.23.1 Pacific Diabetes Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 54
5.24 Pancreum, LLC Company Overview 55
5.24.1 Pancreum, LLC Pipeline Products & Ongoing Clinical Trials Overview 55
5.25 PharmaCyte Biotech Inc Company Overview 56
5.25.1 PharmaCyte Biotech Inc Pipeline Products & Ongoing Clinical Trials Overview 56
5.26 Polytechnic University of Valencia Company Overview 57
5.26.1 Polytechnic University of Valencia Pipeline Products & Ongoing Clinical Trials Overview 57
5.27 Rensselaer Polytechnic Institute Company Overview 58
5.27.1 Rensselaer Polytechnic Institute Pipeline Products & Ongoing Clinical Trials Overview 58
5.28 Schneider Children's Medical Center of Israel Company Overview 59
5.28.1 Schneider Children's Medical Center of Israel Pipeline Products & Ongoing Clinical Trials Overview 59
5.29 Senseonics Holdings, Inc. Company Overview 60
5.29.1 Senseonics Holdings, Inc. Pipeline Products & Ongoing Clinical Trials Overview 60
5.30 TecMed, Inc. Company Overview 63
5.30.1 TecMed, Inc. Pipeline Products & Ongoing Clinical Trials Overview 63
5.31 The University of Newcastle Company Overview 64
5.31.1 The University of Newcastle Pipeline Products & Ongoing Clinical Trials Overview 64
5.32 TypeZero Technologies LLC Company Overview 65
5.32.1 TypeZero Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview 65
5.33 Ultradian Diagnostics LLC Company Overview 68
5.33.1 Ultradian Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 68
5.34 Universidad Autonoma de Madrid Company Overview 69
5.34.1 Universidad Autonoma de Madrid Pipeline Products & Ongoing Clinical Trials Overview 69
5.35 University of California San Francisco Company Overview 70
5.35.1 University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview 70
5.36 University of California Santa Barbara Company Overview 71
5.36.1 University of California Santa Barbara Pipeline Products & Ongoing Clinical Trials Overview 71
5.37 University of Cambridge Company Overview 73
5.37.1 University of Cambridge Pipeline Products & Ongoing Clinical Trials Overview 73
5.38 University of Florida Company Overview 78
5.38.1 University of Florida Pipeline Products & Ongoing Clinical Trials Overview 78
5.39 XERIS Pharmaceuticals Inc Company Overview 79
5.39.1 XERIS Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 79
6 Artificial Pancreas - Recent Developments 80
6.1 Jul 26, 2017: PharmaCyte Biotech Appoints Dr. Linda S. Sher as Chief Medical Officer 80
6.2 Jul 10, 2017: PharmaCyte Biotech Appoints Dr. Michael M. Abecassis to Board of Directors 81
6.3 Jun 26, 2017: Medtronic Announces Outcomes-Based Agreement with Aetna for Type 1 and Type 2 Diabetes Patients 82
6.4 Jun 22, 2017: Phase 2a trial results support development of dasiglucagon in the iLet pump system for type 1 diabetes 82
6.5 Jun 12, 2017: Insulet Presents Positive Omnipod Horizon Hybrid Closed-Loop Study Results in Children 84
6.6 Jun 07, 2017: Medtronic Initiates U.S. Launch of World's First Hybrid Closed Loop System for Type 1 Diabetes 84
6.7 May 30, 2017: Insulet Appoints Bret Christensen as Chief Commercial Officer 86
6.8 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results 86
6.9 May 08, 2017: Insulet Reports First Quarter 2017 Financial Results 89
6.10 May 02, 2017: PharmaCyte Biotech Appoints Thomas Yuen to Board of Directors 90
6.11 Apr 28, 2017: Artificial pancreas benefits young children, trial shows 91
6.12 Apr 20, 2017: Cellnovo announces that Diabeloop is launching a CE marking Registration Study on Artificial Pancreas with Cellnovo pump 91
6.13 Apr 19, 2017: PharmaCyte Biotech Receives the 2017 "Pipelines of Promise" Award from BIO International 92
6.14 Apr 03, 2017: PharmaCyte Biotech Appoints Dr. Mark Rabe Director of Cannabis Program Development 93
6.15 Mar 30, 2017: ConvaTec Expands Unomedical Manufacturing Technology Partnership with Medtronic Diabetes to Meet Growing Demand 94
6.16 Mar 13, 2017: PharmaCyte Biotech Names Dr. Leonard Makowka as Senior Strategic Advisor 94
6.17 Mar 06, 2017: Important Update On Minimed 670G Availability And The Priority Access Program 95
6.18 Feb 27, 2017: Insulet Reports Fourth Quarter and Full Year 2016 Financial Results 96
6.19 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results 98
6.20 Feb 17, 2017: Insulet Presents Strong Omnipod Horizon Hybrid Closed-Loop Study Results at ATTD in Paris 101
6.21 Feb 13, 2017: National Institutes of Health Funds Schneider Children's Medical Center and International Diabetes Center Closed-Loop System Research 102
6.22 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors 103
6.23 Jan 09, 2017: Xeris Pharmaceuticals Announces Appointment of Paul R. Edick as President and CEO 103
6.24 Jan 05, 2017: Cellnovo and Diabeloop Update on Artificial Pancreas 104
6.25 Dec 19, 2016: Bionic pancreas system successfully controls blood sugar without risk of hypoglycemia 105
6.26 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results 106
6.27 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report 109
6.28 Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction 110
6.29 Nov 03, 2016: Insulet Reports Third Quarter 2016 Financial Results 111
6.30 Oct 19, 2016: Insulet Announces Board and Management Changes 112
6.31 Sep 28, 2016: FDA approves first automated insulin delivery device for type 1 diabetes 112
6.32 Sep 15, 2016: The Journal of the American Medical Association Publishes Medtronic's Hybrid Closed Loop System Pivotal Trial Results 113
6.33 Sep 15, 2016: Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services 114
6.34 Sep 13, 2016: Insulet Enrolls First Patients in Clinical Trial for its Omnipod Artificial Pancreas System 115
6.35 Sep 06, 2016: Insulet to Establish Highly-Automated Manufacturing Operation in the United States 116
6.36 Sep 06, 2016: Insulet Announces Executive Appointments 116
6.37 Sep 05, 2016: Artificial pancreas trial in young children with diabetes receives 4.6millon grant from European Commission 117
6.38 Aug 25, 2016: Medtronic Reports First Quarter Financial Results 118
7 Appendix 121
7.1 Methodology 121
7.2 About GlobalData 124
7.3 Contact Us 124
7.4 Disclaimer 124
1.1 List of Tables
Table 1: Artificial Pancreas - Pipeline Products by Stage of Development 10
Table 2: Artificial Pancreas - Pipeline Products by Territory 11
Table 3: Artificial Pancreas - Pipeline Products by Regulatory Path 12
Table 4: Artificial Pancreas - Pipeline Products by Estimated Approval Date 13
Table 5: Artificial Pancreas - Ongoing Clinical Trials 14
Table 6: Artificial Pancreas Companies - Pipeline Products by Stage of Development 15
Table 7: Artificial Pancreas - Pipeline Products by Stage of Development 17
Table 8: Admetsys Corporation Pipeline Products & Ongoing Clinical Trials Overview 19
Table 9: Admetsys Smart Pancreas - Product Status 19
Table 10: Admetsys Smart Pancreas - Product Description 19
Table 11: Advanced Biosensors-Ohio, Llc Pipeline Products & Ongoing Clinical Trials Overview 20
Table 12: Artificial Pancreas - Product Status 20
Table 13: Artificial Pancreas - Product Description 20
Table 14: Animas Corp Pipeline Products & Ongoing Clinical Trials Overview 21
Table 15: Hypoglycemia-Hyperglycemia Minimizer System - Product Status 21
Table 16: Hypoglycemia-Hyperglycemia Minimizer System - Product Description 21
Table 17: Beta Bionics Inc Pipeline Products & Ongoing Clinical Trials Overview 22
Table 18: iLet - Product Status 22
Table 19: iLet - Product Description 22
Table 20: Beta Bionics Inc - Ongoing Clinical Trials Overview 23
Table 21: iLet - A Multicenter Study of Outpatient Automated Blood Glucose Control with a Bihormonal Bionic Pancreas 24
Table 22: iLet - Closed-loop Glucagon Administration for the Automated Prevention and Treatment of Hypoglycemia 24
Table 23: Beta-O2 Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 25
Table 24: ßAir Bio-artificial Pancreas - Product Status 25
Table 25: ßAir Bio-artificial Pancreas - Product Description 25
Table 26: Beta-O2 Technologies Ltd - Ongoing Clinical Trials Overview 26
Table 27: ßAir Bio-artificial Pancreas - An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets within the Bioartificial Pancreas Beta-Air in Patients with Type 1 Diabetes Mellitus 27
Table 28: Bigfoot Biomedical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 28
Table 29: Smartloop Automated Insulin Delivery System - Product Status 28
Table 30: Smartloop Automated Insulin Delivery System - Product Description 28
Table 31: BioTex Inc Pipeline Products & Ongoing Clinical Trials Overview 29
Table 32: Artificial Pancreas - Product Status 29
Table 33: Artificial Pancreas - Product Description 29
Table 34: Cerco Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 30
Table 35: Islet Sheet - Product Status 30
Table 36: Islet Sheet - Product Description 30
Table 37: Converge Biotech, Inc. Pipeline Products & Ongoing Clinical Trials Overview 31
Table 38: Bioartificial Pancreas System - Product Status 31
Table 39: Bioartificial Pancreas System - Product Description 31
Table 40: Covalor Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview 32
Table 41: Artificial Pancreas - Product Status 32
Table 42: Artificial Pancreas - Product Description 32
Table 43: De Montfort University Pipeline Products & Ongoing Clinical Trials Overview 33
Table 44: InSmart Artificial Pancreas - Product Status 33
Table 45: InSmart Artificial Pancreas - Product Description 33
Table 46: Debiotech SA Pipeline Products & Ongoing Clinical Trials Overview 34
Table 47: Next Generation Artificial Pancreas - Product Status 34
Table 48: Next Generation Artificial Pancreas - Product Description 34
Table 49: Defymed Inc Pipeline Products & Ongoing Clinical Trials Overview 35
Table 50: MAILPAN - Product Status 35
Table 51: MAILPAN - Product Description 35
Table 52: Diabeloop Pipeline Products & Ongoing Clinical Trials Overview 36
Table 53: Diabeloop Artificial Pancreas - Product Status 36
Table 54: Diabeloop Artificial Pancreas - Product Description 36
Table 55: Diabeloop - Ongoing Clinical Trials Overview 37
Table 56: Diabeloop Artificial Pancreas - Crossover Evaluation of the Safety and the Efficacy of Artificial Pancreas Diabeloop for Three Months at Home in Comparison with Conventional Treatment by External Insulin Pump in Patients with Type 1 Diabetes 38
Table 57: Giner Inc Pipeline Products & Ongoing Clinical Trials Overview 39
Table 58: BAPIOS System - Product Status 39
Table 59: BAPIOS System - Product Description 39
Table 60: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 40
Table 61: Bio-inspired Artificial Pancreas - Product Status 40
Table 62: Bio-inspired Artificial Pancreas - Product Description 40
Table 63: Inreda Diabetic BV Pipeline Products & Ongoing Clinical Trials Overview 41
Table 64: Bi-Hormonal Artificial Pancreas - Product Status 41
Table 65: Bi-Hormonal Artificial Pancreas - Product Description 41
Table 66: Insulet Corp Pipeline Products & Ongoing Clinical Trials Overview 42
Table 67: Omnipod Horizon Hybrid Closed Loop System - Product Status 42
Table 68: Omnipod Horizon Hybrid Closed Loop System - Product Description 42
Table 69: Kencak LLC Pipeline Products & Ongoing Clinical Trials Overview 43
Table 70: BioArtificial Pancreas - Product Status 43
Table 71: BioArtificial Pancreas - Product Description 43
Table 72: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 44
Table 73: MiniMed 640G System - Product Status 44
Table 74: MiniMed 640G System - Product Description 45
Table 75: MiniMed 670G - Product Status 45
Table 76: MiniMed 670G - Product Description 45
Table 77: Third-Generation Artificial Pancreas System - Product Status 46
Table 78: Third-Generation Artificial Pancreas System - Product Description 46
Table 79: Medtronic plc - Ongoing Clinical Trials Overview 47
Table 80: MiniMed 670G - A Crossover Study Comparing Two Automated Insulin Delivery System Algorithms (PID vs. PID + Fuzzy Logic) in Adolescents and Young Adults with Type 1 Diabetes 48
Table 81: MiniMed 670G - Clinical Startup of the 670G Closed Loop Insulin Delivery System 48
Table 82: MiniMed 670G - Effect of Hybrid Closed-loop Insulin Delivery on Glucose Counterregulation in Long Standing Type 1 Diabetes: A Proof of Concept, Mechanistic, Single-arm Clinical Trial 48
Table 83: MiniMed 670G - Feasibility Study to Evaluate the Hybrid-Logic Closed Loop System in Type 1 Diabetes -Single-arm, Single-center, in Clinic Study-The DREAMED Trail 49
Table 84: MiniMed 670G - Multi-center, Randomized, Adaptive, Controlled Trial in Adult and Pediatric Patients with Type 1 Diabetes Using Hybrid Closed Loop System at Home 49
Table 85: MiniMed 670G - Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects with Type 1 Diabetes 49
Table 86: MiniMed 640G System - An Open-label, Multi-center, Randomized, 2-period Cross-over Study to Assess the Efficacy and Safety of Closed Loop Insulin Delivery Using Diluted Insulin in Comparison with Closed Loop with Non-diluted Insulin Over 21 Days in Children with Type 1 Diabetes Aged 1 to 7 Years in the Home Setting 50
Table 87: MiniMed 640G System - An Open-label, Multicenter, Randomized, Single-period, Parallel Design Study to Assess the Effect of Closed Loop Insulin Delivery from Onset of Type 1 Diabetes in Youth on Residual Beta Cell Function Compared to Standard Insulin Therapy 50
Table 88: MiniMed 640G System - Evaluation of Two Different Glucose Monitoring Treatments and Their Impact on Time in Target, Sleep and Quality of Life in Children with Type 1 Diabetes and Primary Caregivers 51
Table 89: MiniMed 640G System - Study of MiniMed 640G Insulin Pump With SmartGuard in Prevention of Low Glucose Events in Adults With Type 1 Diabetes 51
Table 90: MiniMed 640G System - Study of Minimed 640G Insulin Pump with SmartGuard in Prevention of Low Glucose Events in Adults with Type 1 Diabetes at Risk of Severe Hypoglycemia 51
Table 91: Miromatrix Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 52
Table 92: Miro Pancreas - Product Status 52
Table 93: Miro Pancreas - Product Description 52
Table 94: Nikkiso Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 53
Table 95: Artificial Pancreas - Product Status 53
Table 96: Artificial Pancreas - Product Description 53
Table 97: Pacific Diabetes Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 54
Table 98: Artificial Endocrine Pancreas - Product Status 54
Table 99: Artificial Endocrine Pancreas - Product Description 54
Table 100: Pancreum, LLC Pipeline Products & Ongoing Clinical Trials Overview 55
Table 101: Genesis Artificial Pancreas - Product Status 55
Table 102: Genesis Artificial Pancreas - Product Description 55
Table 103: PharmaCyte Biotech Inc Pipeline Products & Ongoing Clinical Trials Overview 56
Table 104: Bio-Artificial Pancreas - Product Status 56
Table 105: Bio-Artificial Pancreas - Product Description 56
Table 106: Polytechnic University of Valencia Pipeline Products & Ongoing Clinical Trials Overview 57
Table 107: ClosedLoop 4Meal Control - Product Status 57
Table 108: ClosedLoop 4Meal Control - Product Description 57
Table 109: Rensselaer Polytechnic Institute Pipeline Products & Ongoing Clinical Trials Overview 58
Table 110: Closed-Loop Artificial Pancreas System - Product Status 58
Table 111: Closed-Loop Artificial Pancreas System - Product Description 58
Table 112: Schneider Children's Medical Center of Israel Pipeline Products & Ongoing Clinical Trials Overview 59
Table 113: MD-Logic Artificial Pancreas - Product Status 59
Table 114: MD-Logic Artificial Pancreas - Product Description 59
Table 115: Senseonics Holdings, Inc. Pipeline Products & Ongoing Clinical Trials Overview 60
Table 116: Eversense CGM System Integrated With inControl And Accu-Chek Insight Insulin Pump - Product Status 60
Table 117: Eversense CGM System Integrated With inControl And Accu-Chek Insight Insulin Pump - Product Description 60
Table 118: Senseonics Holdings, Inc. - Ongoing Clinical Trials Overview 61
Table 119: Eversense CGM System Integrated With inControl And Accu-Chek Insight Insulin Pump - Clinical Acceptance of the Artificial Pancreas: The International Diabetes Closed Loop (iDCL) Trial Research Site Training Protocol 62
Table 120: Eversense CGM System Integrated With inControl And Accu-Chek Insight Insulin Pump - Clinical Acceptance of the Artificial Pancreas: The International Diabetes Closed Loop (iDCL) Trial: A Randomized Clinical Trial to Assess the Efficacy of Adjunctive Closed Loop Control Versus Sensor-augmented Pump Therapy in the Management of Type 1 Diabetes 62
Table 121: TecMed, Inc. Pipeline Products & Ongoing Clinical Trials Overview 63
Table 122: TecMed Artificial Pancreas - Product Status 63
Table 123: TecMed Artificial Pancreas - Product Description 63
Table 124: The University of Newcastle Pipeline Products & Ongoing Clinical Trials Overview 64
Table 125: Closed Glucose-Sensing Insulin-Delivery System - Product Status 64
Table 126: Closed Glucose-Sensing Insulin-Delivery System - Product Description 64
Table 127: TypeZero Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview 65
Table 128: inControl - Product Status 65
Table 129: inControl - Product Description 65
Table 130: TypeZero Technologies LLC - Ongoing Clinical Trials Overview 66
Table 131: inControl - Clinical Acceptance of the Artificial Pancreas: The International Diabetes Closed Loop (iDCL) Trial Research Site Training Protocol 67
Table 132: inControl - Clinical Acceptance of the Artificial Pancreas: The International Diabetes Closed Loop (iDCL) Trial: A Randomized Clinical Trial to Assess the Efficacy of Adjunctive Closed Loop Control Versus Sensor-augmented Pump Therapy in the Management of Type 1 Diabetes 67
Table 133: inControl - Examination of New Control Algorithm of inControl AP 67
Table 134: Ultradian Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 68
Table 135: Artificial Pancreas - Product Status 68
Table 136: Artificial Pancreas - Product Description 68
Table 137: Universidad Autonoma de Madrid Pipeline Products & Ongoing Clinical Trials Overview 69
Table 138: Predictive Rule-Based Algorithm - Product Status 69
Table 139: Predictive Rule-Based Algorithm - Product Description 69
Table 140: University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview 70
Table 141: Bioartificial Pancreas - Product Status 70
Table 142: Bioartificial Pancreas - Product Description 70
Table 143: University of California Santa Barbara Pipeline Products & Ongoing Clinical Trials Overview 71
Table 144: Closed-Loop Artificial Pancreas - Product Status 71
Table 145: Closed-Loop Artificial Pancreas - Product Description 71
Table 146: Pediatric Artificial Pancreas - Product Status 72
Table 147: Pediatric Artificial Pancreas - Product Description 72
Table 148: University of Cambridge Pipeline Products & Ongoing Clinical Trials Overview 73
Table 149: Artificial Pancreas - Product Status 73
Table 150: Artificial Pancreas - Product Description 73
Table 151: Florence D2A System - Product Status 74
Table 152: Florence D2A System - Product Description 74
Table 153: University of Cambridge - Ongoing Clinical Trials Overview 75
Table 154: Florence D2A System - Closing the Loop in Adults with Type 1 Diabetes and HbA1C Less than 7.5% Under Free Living Conditions 76
Table 155: Artificial Pancreas - An Open-label, Multi-center, Randomized, 2-period Cross-over Study to Assess the Efficacy and Safety of Closed Loop Insulin Delivery Using Diluted Insulin in Comparison with Closed Loop with Non-diluted Insulin Over 21 Days in Children with Type 1 Diabetes Aged 1 to 7 Years in the Home Setting 77
Table 156: University of Florida Pipeline Products & Ongoing Clinical Trials Overview 78
Table 157: Bioartificial Pancreas - Type 1 Diabetes - Product Status 78
Table 158: Bioartificial Pancreas - Type 1 Diabetes - Product Description 78
Table 159: XERIS Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 79
Table 160: G-Pump - BP - Product Status 79
Table 161: G-Pump - BP - Product Description 79
Table 162: Glossary 123
1.2 List of Figures
Figure 1: Artificial Pancreas - Pipeline Products by Stage of Development 10
Figure 2: Artificial Pancreas - Pipeline Products by Territory 11
Figure 3: Artificial Pancreas - Pipeline Products by Regulatory Path 12
Figure 4: Artificial Pancreas - Pipeline Products by Estimated Approval Date 13
Figure 5: Artificial Pancreas - Ongoing Clinical Trials 14
